BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31164904)

  • 1. Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response.
    Jia N; Sun Z; Gao X; Cheng Y; Zhou Y; Shen C; Chen W; Wang X; Shi R; Li N; Zhou J; Bai C
    Front Genet; 2019; 10():470. PubMed ID: 31164904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
    Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
    Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer.
    Hsu HC; Lapke N; Wang CW; Lin PY; You JF; Yeh CY; Tsai WS; Hung HY; Chiang SF; Chen HC; Chen SJ; Hsu A; Yang TS
    Mol Cancer Ther; 2018 Oct; 17(10):2238-2247. PubMed ID: 29997152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy.
    Yang W; Zou J; Li Y; Liu R; Yan Z; Chen S; Zhao X; Guo W; Huang M; Li W; Zhu X; Chen Z
    Front Oncol; 2022; 12():830816. PubMed ID: 35280779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second‑line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study.
    He Q; Shi X; Yan J; Wu M; Gu C; Yu X
    Mol Clin Oncol; 2024 Apr; 20(4):29. PubMed ID: 38414510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer.
    Lin CY; Shen MY; Chen WT; Yang CA
    J Pers Med; 2023 Jun; 13(7):. PubMed ID: 37511664
    [No Abstract]   [Full Text] [Related]  

  • 9. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
    Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
    Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
    Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
    Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ctDNA Clearance and Radiographic Resolution of Disease in Response to Dual Checkpoint Inhibition in Metastatic Microsatellite Stable Colorectal Cancer with a High Tumor Mutation Burden.
    Schneider CJ; Krainock M; Malashevich AK; Malhotra M; Olshan P; Billings PR; Aleshin A
    Case Rep Oncol; 2021; 14(2):849-853. PubMed ID: 34248549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
    Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
    JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy.
    Lee S; Park YS; Chang WJ; Choi JY; Lim A; Kim B; Lee SB; Lee JW; Kim SH; Kim J; Kwak JM; Yoon KC; Lee SH; Kim YH
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
    Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
    Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients.
    Yamauchi M; Urabe Y; Ono A; Miki D; Ochi H; Chayama K
    Int J Cancer; 2018 Apr; 142(7):1418-1426. PubMed ID: 29134647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer.
    Thomsen CB; Hansen TF; Andersen RF; Lindebjerg J; Jensen LH; Jakobsen A
    Ther Adv Med Oncol; 2020; 12():1758835920918472. PubMed ID: 32518596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer.
    Doleschal B; Kirchweger P; Schwendinger S; Kupferthaler A; Burghofer J; Webersinke G; Jukic E; Wundsam H; Biebl M; Petzer A; Rumpold H
    Ther Adv Med Oncol; 2023; 15():17588359231200462. PubMed ID: 37786537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.